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Background and Aims: The present systematic revierv aims rt comp:rring both the
.lfic,r.y and salety of fast-acting insulin lispro analogue (Lispro) and human regular
insulin (Rcgular) in type ldiabcric paticnts trcrtcd rvith ct>ntinuous subcutane<>us
insulin infusion (CSI l).
MaterialsandMethods: Randomised clinical trials (RCTs) comparing Lispro vs
Regular in CSII-treate<J typc I diabetic paticnts were extensivcly searched in the
litelature, and the following efficacy and safety asPects were studied: l) 1-h or 2-h
postprandial hyperglycaemia; 2) HbAlc level;3) the inciclencc oFscvcrc hypoglycae-
mia; :rnd 4) thc risk of kctoacidosis.
Results: Lispro was compared with Regular during CSII in one double-blind cross-
over RCT (; = 30) ancl in 5 opcn-label crossove r RCTs (total: n = 262), each o[2 x 2-
to 4-month cluration. All these RCTs dcrnonstrated significant reductron in post-
pranclial hy;rerglycaemi:r (wcighted mern difFerence or wN{f): - l,(r(r mmol,4; p <
it.ttttt;n = içzlà"a 4irninution in HbAlc lcvel (wlvli): *l).24o/o; p < 0 00 l), rvirhout
any significanr difference in rhe incidence of severc hypogiycaemia (wlvlD: - 0.17
hypor/p^ri.nt/30 clays; NS). in conrrasr, in an open-label parallel 4-month study, no
,igï;n.^n, 4iffercnces in postpranclial hyperglycaemia, HbA I c levcl and incidcncc oF
hyp,,gly.""mia could be cvide ncccl bctwcen Lispro (n = 59) and Regular (n = 28)' In a
,ri^t i..ring thc switch from Regular ro Lispro in 62 diabetic paticnts, a050va rerhc-
tirn in HbAIc lcvcl (p < 0.001)was mlintaincd aftcr 20 months o[(]SII with Lispro.
None of these RCTs pointcd our a higher risk of ketoacidotic episodes when using
Lispro instelcl c,f Rcguiar. Intcrcstingly, trvo cxpcrimcntitl crossovcr trirls (n = 7 and
l0) r.lcmonstratccl an c:rrlicr:rnd higher risc in blood glucosc and kctonc bodics, up to
3-5 hours afte r acute CSII interruption, when using Lispro instead o[ Regular' Htlw-
ever, such early differences were not observed in one parallel trial comparing CSII
int.rruption with Lispro (n = 9) vs Rcgular (n = 9), and cluite similar latc mctabolic
deteriorations were reported after 8-9 hours with both types of insulin in the two
studies resting such a prolonged cSII interruption. Finally, despite the common use
ol CSII cluriàg pregnancy, ir is n,rt.*,,rrhy that thc salery .f Lispr. hes n.t bcen
validated in lerge RCTs in CSII-treated prcgnxnt women'
Conclusion: As cc,mparecJ with human rcgular insulin, insulin lispro rcsultcd in sig-
nificantly lower posrprândial hype rglycae mia :rnd HbA lc lcvels in cSII-tre ared type
I diabetic patie nts, wirhour significanr di[fle rence s in hypoglycaemic episode s The
carlie r metabolic de tcrioration in case of acutc intcrruption of insulin lrspro in[usion
was nor rssociated u,ith a higher rate oIketoacidosis, at least in patie nts prrticip:rting
to clinical trials.
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